Advisory Research Inc. lessened its holdings in shares of Sanofi SA (NYSE:SNY) by 94.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,589 shares of the company’s stock after selling 269,115 shares during the quarter. Advisory Research Inc.’s holdings in Sanofi were worth $627,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the stock. Bank of Nova Scotia Trust Co. purchased a new position in Sanofi during the 3rd quarter valued at approximately $125,000. Bronfman E.L. Rothschild L.P. grew its holdings in Sanofi by 46.0% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 4,325 shares of the company’s stock valued at $186,000 after buying an additional 1,362 shares in the last quarter. Toronto Dominion Bank grew its holdings in Sanofi by 4.6% during the 2nd quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after buying an additional 180 shares in the last quarter. SeaCrest Wealth Management LLC purchased a new position in Sanofi during the 4th quarter valued at approximately $200,000. Finally, Mraz Amerine & Associates Inc. purchased a new position in Sanofi during the 3rd quarter valued at approximately $204,000. 9.07% of the stock is currently owned by institutional investors.
Several research firms have weighed in on SNY. Sanford C. Bernstein restated a “market perform” rating and set a $45.00 price target (down previously from $50.00) on shares of Sanofi in a report on Thursday, February 8th. UBS Group restated a “neutral” rating on shares of Sanofi in a report on Monday, January 15th. ValuEngine cut Sanofi from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a report on Wednesday, December 6th. Finally, TheStreet cut Sanofi from a “b-” rating to a “c+” rating in a report on Tuesday, February 13th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company’s stock. Sanofi currently has an average rating of “Hold” and a consensus price target of $49.33.
Sanofi (NYSE:SNY) last announced its earnings results on Wednesday, February 7th. The company reported $0.62 EPS for the quarter, missing the Zacks’ consensus estimate of $0.69 by ($0.07). The company had revenue of $8.69 billion during the quarter, compared to analysts’ expectations of $8.65 billion. Sanofi had a return on equity of 37.09% and a net margin of 23.25%. Sanofi’s revenue for the quarter was down 2.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.25 EPS. research analysts forecast that Sanofi SA will post 3.37 earnings per share for the current year.
The business also recently announced an annual dividend, which will be paid on Monday, June 4th. Stockholders of record on Thursday, May 10th will be issued a $1.8609 dividend. This is a boost from Sanofi’s previous annual dividend of $1.58. The ex-dividend date is Wednesday, May 9th. This represents a dividend yield of 4.72%. Sanofi’s payout ratio is 58.82%.
COPYRIGHT VIOLATION WARNING: “Sanofi SA (SNY) Position Cut by Advisory Research Inc.” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/02/19/sanofi-sa-sny-position-cut-by-advisory-research-inc.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.